Abstract:Introduction: Despite significant advancements in scientific and diagnostic technologies, clinical trials for cancer often fail due to a lack of efficacy. Access to a platform that accurately predicts patient response is crucial to increase the success rate of clinical studies, and to minimize unnecessary exposure to ineffective and potentially harmful drug testing for patients. Because of the complexity of the disease, it would be beneficial to deploy patient samples for drug testing in a side-by-side comparison during the clinical trial. An accurate prediction of patient response earlier in the clinical study would aid decision making to determine the appropriate duration of treatment for each patient. Methods: We developed a 3D human cell co-culture model using our proprietary MPS technology, the Curio-spheroid Curiochip. Using patient samples isolated and expanded from either ascites fluids or biopsies to recapitulate the clinical phenotypes of advanced gastric cancer, we quantified the migratory properties of the patient cancer cells (i.e., the unique metastatic potential), and measured the level of secretion of VEGF. Somatic mutational analyses using NGS and RNAseq were performed for subtyping and clustering the samples. The patient cancer cells were expanded within 2 weeks post-collection, and used to form a spheroid that was loaded into a hydrogel embedded within the Curio-Spheroid, enabling the patient spheroids to interact through the hydrogel with neighboring (healthy) human endothelial cells. The patient spheroids induced aggressive vasculogenesis in the co-culture model, which was subdued by the anti-VEGFR2 antibody Ramucirumab. The platform was retrospectively validated with the Standard-of-Care (SOC) treatments that the patients received. Results: The patient cell testing took 3-4 weeks from sample collection to imaging. The patient cells preserved their migratory capacity, pro-angiogenic potential and drug responses in the vascularized model. The dose responses to SOC in the platform were consistent with the actual patient response assessments based on RECIST criteria, supporting the potential to use this platform to accurately predict patient clinical responses. Conclusions: The Curio-spheroid 3D co-culture model of vascularized gastric cancer provides a dynamic microenvironment to preserve the phenotypes of the patient cells and cell-cell interactions that are known to influence drug responses. This platform is compatible with high-throughput screening (HTS) for target or drug discovery with a good assay window. The ability to accurately recapitulate patient responses to SOC in the clinic make the Curio-Spheroid platform a promising method to test patient samples and measure drug responses of patients in real time during ongoing clinical trials. Citation Format: Yeongmin Choi, Sumin Kim, Youngsook Song, Yangji Kim, Jin Hawn Jang, Suryong Kim, Jihye Baek, Delaney Donnelly, Bushra Rajiput, Byungjun Lee, Woo Sun Kwon, Tsung-Li Liu, Kyusuk Baek, Sanghee Yoo, Sun Young Rha. Development of an in vitro gastric cancer 3D co-culture platform using a microphysiological system (MPS) to improve outcomes in oncology clinical trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6789.

Abstract 3206: Three-dimensional tumor angiogenesis mapping in metastatic gastric cancer patients

Comprehensive landscape of tumor angiogenesis via integrating RNA sequencing and three-dimensional microphysiological system.

Abstract 1179: A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response

Abstract 6665: A spatiotemporal cell atlas of human gastric malignancy reveals mechanisms underlying metastasis and immunotherapy response

Abstract 6789: Development of an in vitro gastric cancer 3D co-culture platform using a microphysiological system (MPS) to improve outcomes in oncology clinical trials

Abstract 5667: Intratumoral heterogeneity in gastric cancer related with survival and tumor microenvironment

Abstract 7400: AI-driven multimodal 3D tumor modeling with spatial molecular insights for predicting ICI response in gastric cancer

Abstract 229: Molecular-genomic characterization of metastatic gastric cancer organoids and establishment of organoid-immune cell co-culture model

Abstract 5848: Unraveling c-MET targeting resistance mechanisms in gastric cancer via single-cell transcriptome analysis; Novel therapeutic target discovery of ERO1A and VEGFA

Abstract 5075: Transcriptomic landscape of tumor microenvironment in gastric cancer in treatment with different types of cancer drugs

Abstract 1561: Identification of tumor-associated macrophages promoting early-stage metastasis during peritoneal dissemination in gastric cancer

Abstract 2451: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis

Abstract 5396: Vascularized gastric cancer 3D co-culture model using a microphysiological system as an oncolytic virus testing platform

Abstract 4776: The role of angiogenesis in gastric tumorigenesis

Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer.

Tumor progression-dependent angiogenesis in gastric cancer and its potential application

Abstract 1389: Single-cell Sequencing to Identify Genetic Variant Accelerating Shedding of CTCs into Peripheral Blood in Gastric Cancer Patients

Assessment Of Regulation Of Rhoa Activity Panel Mutations As A Predictive Biomarker In Patients With Gastric Cancer

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer

Bioinformatics Evaluation of a Novel Angiogenesis Related Genes-Based Signature for Predicting Prognosis and Therapeutic Efficacy in Patients with Gastric Cancer.

Abstract 6200: Single-cell analyses unravel novel immune and tumor cell characteristics linked to the response to neoadjuvant immune checkpoint blockade in patients with gastric cancer